|Bid||153.05 x 1100|
|Ask||153.05 x 800|
|Day's Range||150.89 - 154.95|
|52 Week Range||101.36 - 164.90|
|Beta (5Y Monthly)||0.26|
|PE Ratio (TTM)||25.41|
|Earnings Date||Jul 30, 2020|
|Forward Dividend & Yield||2.96 (1.94%)|
|Ex-Dividend Date||May 14, 2020|
|1y Target Est||156.00|
Eli Lilly announced the company has started an early-stage trial to test its potential treatment for coronavirus. Yahoo Finance’s Anjalee Khemlani breaks down the latest developments.
The number of global cases of the coronavirus that causes COVID-19 climbed above 6 million on Monday, after a weekend dominated by protests across the U.S. at the death of an unarmed black man at the hands of a white police officer in Minneapolis last week.
The big pharma's collaboration with AbCellera to create a coronavirus treatment is sprinting forward.
Major stock indexes were higher early Monday on rising U.S.-China tensions. Pfizer dove 7% on a failed drug trial.
Eli Lilly said its early stage vaccine trial is "the world's first study of a potential antibody treatment designed to fight COVID-19"
FDA approves Lilly's (LLY) Cyramza as a combination regimen for metastatic EGFR-mutated non-small cell lung cancer. Cyramza is now approved for six indications to treat four different types of cancers.
Cooper Companies' (COO) fiscal second-quarter performance is likely to reflect better-than-expected performance at CVI and CSI.
Drugmaker Eli Lilly & Co (LLY) said that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (BLA) for its Taltz injection used for the treatment of active non-radiographic inflammatory arthritis affecting joints and the spine.A first-in-class milestone for the treatment, the approval makes Taltz the first antagonist to be approved by the FDA for inflammatory arthritis, also known as Axial Spondyloarthritis (nr-axSpA), which is a disease mainly affecting the sacroiliac joints and the spine, the company said in a statement."We recognize that many patients living with this condition suffer from chronic inflammatory back pain and other symptoms of inflammation for years before being diagnosed, and we're excited about the possibility of these patients finding relief with Taltz," said Patrik Jonsson, senior vice president and president of Lilly Bio-Medicines. "This approval reflects Lilly's continued growth and commitment to supporting rheumatologists and people with autoimmune conditions."The approval is based on the results from a Phase 3 COAST-X trial, which evaluated improvement in signs and symptoms of nr-axSpA compared to placebo. The safety profile of Taltz in patients with nr-axSpA was consistent with previous experience with Taltz in other approved indications, the company said. This marks the fifth approval for Taltz by the FDA since 2016. Since its launch, about 137,000 patients have been treated with Taltz worldwide, with about 80,000 of those in the U.S.Shares in Eli Lilly have been on a winning streak since March 23, advancing 28% to $152.95 as of Friday’s close.Mizuho Securities analyst Vamil Divan has a Hold rating on the stock with a $148 price target amid expectations of slightly lower sales for the company’s Alimta, Taltz and Basaglar. However, overall Divan asserts that Lilly’s product mix is likely to be more resilient to COVID-19 pressures.Wall Street analysts are cautiously optimistic about Lilly’s stock outlook. The Moderate Buy consensus is evenly divided between 4 Buy and 4 Hold ratings. The $163.25 average price target implies 6.7% upside potential in the shares in the coming 12 months. (See Eli Lilly’s stock analysis on TipRanks).Related News: Eli Lilly Starts Dosing Patients In World’s First Covid-19 Antibody Trial Pfizer Loses 6% On Disappointing Ibrance Breast Cancer Outcome Novavax Seeks To Make 1 Billion Covid-19 Vaccine Doses More recent articles from Smarter Analyst: * Abiomed’s Heart Pump Gets FDA Emergency Use Status For Covid-19 Patients * Eli Lilly Starts Dosing Patients In World’s First Covid-19 Antibody Trial * Drugmaker Abbvie Teams Up With Jacobio To Develop Cancer Inhibitor * Immutep Surges In Pre-Market On Positive Efti Cancer Data
Eli Lilly (LLY) has today announced patients have been dosed in the world’s first study of a potential antibody treatment designed to fight COVID-19.This investigational medicine, referred to as LY-CoV555, is the first to emerge from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.Lilly scientists developed the antibody in just three months after AbCellera and the National Institute of Allergy and Infectious Diseases (NIAID) identified it from a blood sample taken from one of the first U.S. patients who recovered from COVID-19. LY-CoV555 is the first potential new medicine specifically designed to attack SARS-CoV-2, the virus that causes COVID-19.The first patients in the study were dosed at major medical centers in the U.S., including NYU Grossman School of Medicine and Cedars-Sinai in Los Angeles. Study J2W-MC-PYAA is a randomized, placebo-controlled, double-blind Phase 1 trial that aims to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of LY-CoV555 following a single dose administered to participants hospitalized for COVID-19.“Antibody therapies such as LY-CoV555 may have potential for both prevention and treatment of COVID-19 and may be particularly important for groups hardest hit by the disease such as the elderly and those with compromised immune systems,” said Daniel Skovronsky, chief scientific officer of Lilly Research Laboratories.“Later this month, we will review the results of this first human study and intend to initiate broader efficacy trials. At the same time… we also are starting large-scale manufacturing of this potential therapy. If LY-CoV555 becomes part of the near-term solution for COVID-19, we want to… [have] several hundred thousand doses available by the end of the year,” continued Skovronsky.Should Phase 1 results show the antibody can be safely administered, Lilly expects to move into the next phase of testing, studying LY-CoV555 in non-hospitalized COVID-19 patients. The company also plans to study the drug in a preventative setting, focusing on vulnerable patient populations.Lilly is researching multiple approaches to treating COVID-19, including examining existing LLY medicines and collaborating with two biotech companies to discover novel antibody treatments for COVID-19.Shares in Eli Lilly are up 16% year-to-date and 2.5% in Monday’s pre-market trading. Wall Street analysts are divided evenly between 4 Buy ratings and 4 Hold ratings, which add up to a Moderate Buy consensus. The $163.25 average price target implies 7% upside potential in the coming 12 months. (See Eli Lilly’s stock analysis on TipRanks).Related News: BioMarin Provides Positive Gene Therapy Update For Severe Hemophilia A Pfizer Loses 6% On Disappointing Ibrance Breast Cancer Outcome Novavax Seeks To Make 1 Billion Covid-19 Vaccine Doses More recent articles from Smarter Analyst: * Abiomed’s Heart Pump Gets FDA Emergency Use Status For Covid-19 Patients * Eli Lilly’s Taltz Injection Gets FDA Nod For Inflammatory Spine Arthritis Treatment * Drugmaker Abbvie Teams Up With Jacobio To Develop Cancer Inhibitor * Immutep Surges In Pre-Market On Positive Efti Cancer Data
Lilly is one of the several drugmakers and research institutions that are working on vaccines, antivirals and other treatments to help those infected with the fast-spreading novel coronavirus, which has already killed over 370,000 worldwide. An antiviral drug from Gilead Sciences called remdesivir has shown some promise against COVID-19 and is being given to patients by some countries under compassionate or emergency use rule. Lilly said its early stage study will assess safety and tolerability in patients hospitalized with COVID-19 and results are anticipated by the end of June.
Shares of Eli Lilly & Co. gained 0.3% in premarket trading on Monday after the drugmaker said it had started a Phase 1 trial for its experimental COVID-19 antibody treatment. The therapy, LY-CoV555, was developed by Lilly, AbCellera, and the National Institute of Allergy and Infectious Diseases from a blood sample from one of the first people to recover from COVID-19 in the U.S. The placebo-controlled trial will test the antibody treatment in patients hospitalized with COVID-19; Lilly said it expects to release data from the trial by the end of this month. "Antibody therapies such as LY-CoV555 may have potential for both prevention and treatment of COVID-19 and may be particularly important for groups hardest hit by the disease such as the elderly and those with compromised immune systems," Lilly chief scientific officer Daniel Skovronsky said in a news release. Looking ahead, Lilly said it plans to test the therapy in COVID-19 patients who have not been hospitalized and as a preventative tool if the Phase 1 trial demonstrates the drug is safe. Lilly's stock is up 16.3% year-to-date, while the S&P 500 is down 5.7%.
Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Taltz® (ixekizumab) injection 80 mg/mL for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation. Another first-in-class milestone for the treatment, today's approval makes Taltz the first IL-17A antagonist to be approved by the FDA for nr-axSpA.
Eli Lilly and Company (NYSE: LLY) today announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19.
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines, jointly announced with Eli Lilly and Company (Lilly) (NYSE: LLY) the results of TYVYT® (sintilimab injection) ORIENT-2 study, a pivotal clinical study of second-line treatment for locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) (Abstract 4511, Poster 119, 8:00 AM – 11:00 AM, U.S. Central Time, Friday, May 29, 2020).
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines, jointly announced with Eli Lilly and Company (Lilly) (NYSE: LLY) the research results of TYVYT® (sintilimab injection) ORIENT-1 study for the treatment of relapsed or refractory classic Hodgkin's lymphoma (r/r cHL), at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) (Abstract 8034, Poster 367, 8:00 AM – 11:00 AM, U.S. Central Time, Friday, May 29, 2020).
The company produced expectation-beating results. The acquisition of Celgene has gone very well, but shares trade with a multiple of less than 10 times earnings Continue reading...
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
Horseshoe crabs' icy-blue blood is set to remain the drug industry's standard for safety tests after a powerful U.S. group ditched a plan to put on an equal footing a synthetic substitute pushed by Swiss biotech Lonza and animal welfare groups. The crabs' copper-rich blood clots in the presence of bacterial endotoxins and has long been used in tests to detect contamination in shots and infusions. More recently, man-made versions called recombinant Factor C (rFC) from Basel-based Lonza and others have emerged.
Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab injection, 10 mg/mL solution), in combination with erlotinib, for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. With this approval, CYRAMZA has now received six FDA approvals to treat certain types of lung, liver, stomach and colorectal cancers.
With the US regulatory agency's nod, Eli Lilly's (LLY) Tauvid became the first and the only approved radioactive diagnostic agent to image tau NFTs in the brain for effectively evaluating AD patients.
Lilly's new Alzheimer's detection drug, cleared by the FDA for marketing, is a major improvement over the current protocol, a media report says.
Merck (MRK), Glaxo (GSK) and Roche (RHHBY) make progress in coronavirus research efforts.
Veeva Systems' (VEEV) core Subscription business segment performed impressively in Q1.
Shares of Eli Lilly & Co. gained 0.8% in premarket trading on Friday, the day after the Food and Drug Administration (FDA) approved Tauvid, a drug used to help diagnose tau neurofibrillary tangles in people suspected of having Alzheimer's disease. The diagnostic agent is injected into those patients, who then undergo a positron emission tomography (PET) scan. "This is the first drug approved for imaging tau pathology, one of the two neuropathological hallmarks of Alzheimer's disease, and represents a major advance for patients with cognitive impairment being evaluated for the condition," FDA official Dr. Charles Ganley said in a news release on Thursday. Tau and amyloid proteins are associated with the presence of Alzheimer's disease. Shares of Lilly have gained 14.6% year-to-date, while the S&P 500 is down 6.2%.
It's not a treatment for this memory-robbing dementia, but it could help Lilly and its peers find one.